Literature DB >> 12204527

Fas function and tumor progression: use it and lose it.

Laurie B Owen-Schaub1.   

Abstract

Recent studies have provided evidence that Fas and FasL interactions are important in the control of malignant disease and that changes in the level of Fas expression can determine immune escape and therapeutic responses.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12204527     DOI： 10.1016/s1535-6108(02)00099-5

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  7 in total

Review 1.  Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.

Authors:  Nancy Gordon; Eugenie S Kleinerman
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-08       Impact factor: 2.849

2.  Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung.

Authors:  Yutaka Maeda; Tomoshi Tsuchiya; Haiping Hao; David H Tompkins; Yan Xu; Michael L Mucenski; Lingling Du; Angela R Keiser; Takuya Fukazawa; Yoshio Naomoto; Takeshi Nagayasu; Jeffrey A Whitsett
Journal:  J Clin Invest       Date:  2012-11-12       Impact factor: 14.808

3.  Stimulation of Fas agonistic antibody-mediated apoptosis by heparin-like agents suppresses Hsp27 but not Bcl-2 protective activity.

Authors:  Florence Manero; Vesna Ljubic-Thibal; Maryline Moulin; Nadège Goutagny; Jean-Claude Yvin; André-Patrick Arrigo
Journal:  Cell Stress Chaperones       Date:  2004       Impact factor: 3.667

4.  SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.

Authors:  Chunwan Lu; John D Klement; Dafeng Yang; Thomas Albers; Iryna O Lebedyeva; Jennifer L Waller; Kebin Liu
Journal:  Cancer Lett       Date:  2020-02-12       Impact factor: 8.679

Review 5.  Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression.

Authors:  Nirmalya Saha; Andrew G Muntean
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-26       Impact factor: 10.680

Review 6.  Narrative Review of Synergistics Effects of Combining Immunotherapy and Stereotactic Radiation Therapy.

Authors:  François Lucia; Margaux Geier; Ulrike Schick; Vincent Bourbonne
Journal:  Biomedicines       Date:  2022-06-15

7.  The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics.

Authors:  Maximilian Boesch; Alain G Zeimet; Daniel Reimer; Stefan Schmidt; Guenther Gastl; Walther Parson; Franziska Spoeck; Jiri Hatina; Dominik Wolf; Sieghart Sopper
Journal:  Oncotarget       Date:  2014-08-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.